Patent ID: 11925686
Assignee: EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. An ophthalmic implant comprising an ophthalmic material for a light therapy of an ocular disease, comprising:
a matrix material, in which the matrix material is a copolymer obtained by at least one monomer selected from the group consisting of methyl methacrylate, ethyl methacrylate, ethyl acrylate, butyl methacrylate, butyl acrylate, hydroxyethyl methacrylate, and hydroxyethyl acrylate and at least one monomer selected from the group consisting of ethylene glycol dimethacrylate, butanediol dimethacrylate and hexanediol dimethacrylate; and
at least one photosensitizer selected from the group consisting of porphyrins, metalloporphyrins, porphins, chlorophyll or derivatives thereof,
wherein the at least one photosensitizer is fixed inside the matrix material, and the photosensitizer is polymerized with the matrix material,
wherein the amount of the at least one photosensitizer is less than 0.1 wt % relative to the total weight of the matrix material,
wherein the at least one photosensitizer is a photothermal-type photosensitizer capable of generating heat such that, when subjected to a laser light source having a wavelength between 600 nm and 900 nm, the ophthalmic material experiences a temperature increase of about 6° C. to about 12° C., and
wherein the ophthalmic material excludes a UV absorber.